Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Next Previous
Drug Profile

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-sclerostin-monoclonal-antibody-Mereo; BPS-804; UX-143

Latest Information Update: 06 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 29 Dec 2025 Efficacy and adverse events data from the phase III COSMIC trial in Osteogenesis imperfecta released by Ultragenyx Pharmaceutical
  • 29 Dec 2025 Updated efficacy data from the phase II/III ORBIT trial in Osteogenesis imperfecta released by Ultragenyx Pharmaceutical
  • 13 May 2025 Mereo BioPharma announces intention to launch Setrusumab for Osteogenesis imperfecta

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top